Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 6/20 | 0.86 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.86 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 8/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.85 |
| ▸ | THRB | P10828 | 7/20 | 0.85 |
| ▸ | BLM | P54132 | 7/20 | 0.85 |
| ▸ | RECQL | P46063 | 6/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.85 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.85 |
| ▸ | TOP2A | P11388 | 5/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.85 |
| ▸ | STAT6 | P42226 | 4/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182791 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL20382875 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| Hydroxyrubicin SCHEMBL30052370 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL17991858 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18751202 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL14497179 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL13417668 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL19732415 | 0.94 | MEN1 (0.87) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18558770 | 0.93 | MEN1 (0.85) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL10895470 | 0.92 | MEN1 (0.82) | S100A4PAX8HSP90AA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | claimed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | claimed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | claimed |
| US-20200339990-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-10-29 | — | — | US | disclosed |
| EP-3454908-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2018222987-A1 | TARGETED CONSTRUCTS | TARVEDA THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180296685-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-10-18 | — | — | US | disclosed |
| US-20180273948-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180258411-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TVA (ABC), LLC | 2018-09-13 | — | — | US | disclosed |
| EP-3353309-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | Tarveda Therapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017210246-A2 | PENICILLAMINE CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-1900742-A1 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AEterna Zentaris GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | disclosed |
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | disclosed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | disclosed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450480-A2 | Somatostatin Analogues | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296685-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | PAICS, SEPTIN8, SEPTIN7 | S100A4 3618/4885PAX8 3375/4885HSP90AA1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.